Want to see JP:2929 full AI Analyst Report?
2929 Stock Chart & Stats
¥618.00
¥10.00(1.75%)
At close: 4:00 PM EDT
¥618.00
¥10.00(1.75%)
Day’s Range― - ―
52-Week Range¥513.00 - ¥840.00
Previous CloseN/A
Volume102.50K
Average Volume (3M)288.27K
Market Cap
¥19.61B
Enterprise Value¥25.61B
Total Cash (Recent Filing)¥7.79B
Total Debt (Recent Filing)¥17.17B
Price to Earnings (P/E)9.9
Beta0.78
Next Earnings
Dec 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.24%
Share Statistics
EPS (TTM)68.32
Shares Outstanding29,079,000
10 Day Avg. Volume124,400
30 Day Avg. Volume288,266
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.23
Price to Sales (P/S)0.26
P/FCF Ratio-3.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)54.4
Revenue Forecast (FY)¥69.50B
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginA gross margin near 80% indicates the company’s products retain substantial value after direct costs, supporting reinvestment in product development, marketing, and customer acquisition. This provides a durable economic foundation even though operating profitability remains modest.
Improved Profitability On EquityA larger equity base and recovered return on equity suggest improved profitability relative to shareholder capital after the weak 2025 period. If maintained, this combination can strengthen balance-sheet resilience and provide a better foundation for internally funded growth.
Branded, Repeat-Use Consumer ModelSelling branded supplements and functional foods gives Pharma Foods a direct consumer product model with potential for repeat purchasing. Recurring consumption can support customer lifetime value and make revenue less dependent on isolated, one-time transactions.
Bears Say
Sustained Negative Cash FlowRecent negative operating cash flow and deeply negative free cash flow show that reported earnings are not currently converting into cash. Sustained cash consumption can reduce financial flexibility, increase reliance on funding, and constrain investment or shareholder returns.
Elevated LeverageDebt-to-equity remains above 1x despite improvement from 2022–2023, while debt increased again in 2026. This capital structure can limit strategic flexibility and make weaker earnings or cash flows more difficult to absorb without additional financing pressure.
Uneven Revenue And Operating PerformanceThe 2026 revenue decline, modest operating margin, and history of earnings volatility weaken confidence in a stable profit run rate. Even with strong gross margins and a net-income rebound, inconsistent operating performance may hinder predictable growth and planning.
Pharma Foods International Co., Ltd. News
2929 FAQ
What was Pharma Foods International Co., Ltd.’s price range in the past 12 months?
Pharma Foods International Co., Ltd. lowest stock price was ¥513.00 and its highest was ¥840.00 in the past 12 months.
What is Pharma Foods International Co., Ltd.’s market cap?
Pharma Foods International Co., Ltd.’s market cap is ¥19.61B.
When is Pharma Foods International Co., Ltd.’s upcoming earnings report date?
Pharma Foods International Co., Ltd.’s upcoming earnings report date is Dec 16, 2026 which is in 52 days.
How were Pharma Foods International Co., Ltd.’s earnings last quarter?
Pharma Foods International Co., Ltd. released its earnings results on Sep 11, 2026. The company reported ¥105.28 earnings per share for the quarter.
Is Pharma Foods International Co., Ltd. overvalued?
According to Wall Street analysts Pharma Foods International Co., Ltd.’s price is currently Overvalued.
Does Pharma Foods International Co., Ltd. pay dividends?
Pharma Foods International Co., Ltd. pays a Semiannually dividend of ¥12.5 which represents an annual dividend yield of 3.24%. See more information on Pharma Foods International Co., Ltd. dividends here
What is Pharma Foods International Co., Ltd.’s EPS estimate?
Pharma Foods International Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharma Foods International Co., Ltd. have?
Pharma Foods International Co., Ltd. has 29,079,000 shares outstanding.
What happened to Pharma Foods International Co., Ltd.’s price movement after its last earnings report?
Pharma Foods International Co., Ltd. reported an EPS of ¥105.28 in its last earnings report. Following the earnings report the stock price went up 11.254%.
Which hedge fund is a major shareholder of Pharma Foods International Co., Ltd.?
Currently, no hedge funds are holding shares in JP:2929
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pharma Foods International Co., Ltd.
Pharma Foods International Co., Ltd. is a Japanese enterprise dedicated to the research, development, and commercialization of ingredients for functional foods. Its diverse product portfolio features items such as Pharma-GABA, Bonepep, Ovopron (a specific egg yolk globulin), Delicious Catechin, RunPep, and enriched Folic Acid Egg. Additionally, the company offers iHA, a compound recognized for stimulating the body's hyaluronic acid production. Furthermore, Pharma Foods International Co., Ltd. has entered into a licensing arrangement with Mitsubishi Tanabe Pharma Corporation for a novel therapeutic antibody designed to combat autoimmune conditions. The firm was founded in 1997 and maintains its corporate headquarters in Kyoto, Japan.
Technical Analysis
―
Tsumura & Co
―
Wakamoto Pharmaceutical Co., Ltd.
―
Morishita Jintan Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―